Plaintiff Attorneys Seek Final Approval Of Class For Pfizer Drug Purchasers
SAN FRANCISCO - Citing the small number of objectors and saying that an $89 million settlement of consumer claims over Pfizer Inc.'s painkillers Bextra and Celebrex was far less than what plaintiffs thought the claims were worth but far more than Pfizer acknowledged, plaintiffs' attorneys on Aug. 14 filed a motion for final approval of a class (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. M:05-CV-1699, N.D. Calif.; See July 2009, Page 4). Full story on lexis.comFiled by admin at August 31st, 2009 under News